^
Association details:
| Biomarker: | SAMHD1 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug Class: | Platinum alkylating agent |
| Direction: | Resistant |
Evidence:
Source:
Title:
SAMHD1 confers resistance to platinum-based drugs through modification of DNA damage response
Published date:
05/28/2021
Excerpt:
In NSCLC and OC patients, high SAMHD1 expression was associated with shorter time to progression and overall survival (p=.004, p=.014 and p=.003, p=.06, respectively), as well as with lower response in NSCLC (p=.047), strongly validating SAMHD1 as a biomarker in cancer.
Source:
Title:
Prognostic and predictive value of SAMHD1 espression in solid tumors
Published date:
05/28/2021
Excerpt:
...explored the potential rol of SAMHD1 expression in advanced non-small cell lung (NSCLC), ovarian (OC) and breast cancer (BC) patients (p)...22 OC p treated with platinum and/or gemcitabine….SAMHD1 positivity was associated with shorter disease free survival interval (DFS) in OC, NSCLC, and BC p (χ²test; p=.010, p.003, p=.005, respectively)....SAMHD1 positivity was also associated with shorter TTP, OS and OSDC in OC p (p=.003 p=.06, and p=.04, respectively).
